Trials / Not Yet Recruiting
Not Yet RecruitingNCT06194461
LTFU for All Cell and Gene Therapy Studies
A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 64 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Detailed description
This is a multi-centre and multinational basket study that will monitor the long-term safety and tolerability of cell or gene therapies in participants that have taken part in other AstraZeneca cell or gene therapy studies for up to 15 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AZD5851 | Safety follow-up for up to 15 years of subjects who received AZD5851 in study NCT06084884. |
| BIOLOGICAL | AZD0754 | Safety follow-up for up to 15 years of subjects who received AZD0754 in study NCT06267729. |
Timeline
- Start date
- 2025-09-17
- Primary completion
- 2041-11-29
- Completion
- 2041-11-29
- First posted
- 2024-01-08
- Last updated
- 2025-06-27
Locations
25 sites across 4 countries: United States, Australia, Japan, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06194461. Inclusion in this directory is not an endorsement.